Sander Gen, Shirley-Beavan Sam, Stone Katie
1 Harm Reduction International, London, UK.
J Correct Health Care. 2019 Apr;25(2):105-120. doi: 10.1177/1078345819837909.
Despite the fact that a large portion of the prison population is made up of people who use and inject drugs, harm reduction continues to be extremely limited in prison settings. This article begins with a review of drug-related incarceration, drug use in prisons, and HIV and hepatitis C (HCV) prevalence among prisoners globally. It presents the scientific evidence, alongside legal and economic arguments supporting the provision of harm reduction to people who use drugs, both inside and outside of prisons. The article then provides a global overview of the availability, accessibility, and quality of harm reduction services in prisons-specifically needle and syringe programs; opioid substitution therapy; provision of the opioid agonist naloxone; and diagnosis, treatment, and care for HIV, HCV, and tuberculosis.
尽管监狱人口中有很大一部分是吸毒和注射毒品的人,但在监狱环境中,减少伤害的措施仍然极为有限。本文首先回顾了与毒品相关的监禁情况、监狱中的吸毒现象以及全球囚犯中的艾滋病毒和丙型肝炎(HCV)流行情况。它展示了科学证据,以及支持在监狱内外为吸毒者提供减少伤害措施的法律和经济论据。然后,本文对监狱中减少伤害服务的可获得性、可及性和质量进行了全球概述——特别是针头和注射器项目;阿片类药物替代疗法;阿片类激动剂纳洛酮的提供;以及对艾滋病毒、丙型肝炎和结核病的诊断、治疗和护理。